Patents Examined by Johnny F. Railey
-
Patent number: 6124448Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone.Type: GrantFiled: June 7, 1995Date of Patent: September 26, 2000Assignee: The Rockfeller UniversityInventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca, Margherita Maffei
-
Patent number: 6121017Abstract: The present invention relates to methods and compositions for the treatment of body weight disorders, including, but not limited to, obesity. Specifically, the present invention identifies and describes genes which are differentially expressed in body weight disorder states, relative to their expression in normal, or non-body weight disorder states, and/or in response to manipulations relevant to appetite and/or weight regulation. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in body weight disorders and/or appetite and/or body weight regulation. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of body weight disorders. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various body weight disorders, and for the identification of subjects exhibiting a predisposition to such conditions.Type: GrantFiled: October 8, 1997Date of Patent: September 19, 2000Assignee: Millennium Pharmaceuticals, Inc.Inventor: Louis Anthony Tartaglia
-
Patent number: 6121021Abstract: Non-infectious, non-replicating immunogenic HIV-like particles are produced by stable longn-term constitutive expression in mammalian cells by eliminating elements toxic to the mammalian cells. An expression vector contains a nucleic acid molecule comprising a modified HIV genome devoid of long terminal repeats and wherein Tat and vpr sequences are functionally disabled and a constitutive promoter operatively connected to the modified HIV genome for constitutive expression of the modified genome to produce the HIV-like particles.Type: GrantFiled: December 16, 1997Date of Patent: September 19, 2000Assignee: Connaught Laboratories LimitedInventors: Benjamin Rovinski, Fei-Long Yao, Shi Xian Cao
-
Patent number: 6117675Abstract: The invention relates to stem cells isolated from the retina of mammals and retinal cells differentiated from these stem cells. The invention also relates to a method of isolating retinal stem cells and inducing retinal stem cells to produce retinal cells. Retinal stem cells may also be induced in vivo to produce retinal cells. The invention also includes pharmaceuticals made with retinal stem cells or retinal cells which may be used to restore vision lost due to diseases, disorders or abnormal physical states of the retina. The invention includes retinal stem cell and retinal cell culture systems for toxicological assays, for isolating genes involved in retinal differentiation or for developing tumor cell lines.Type: GrantFiled: September 25, 1997Date of Patent: September 12, 2000Assignee: HSC Research and Development Limited PartnershipInventors: Derek van der Kooy, Roderick McInnes, Bernard Chiasson, Vincenzo Tropepe
-
Patent number: 6106824Abstract: The present invention relates to a viral vector capable of the transfer and in vivo expression of growth-associated protein (B-50/GAP-43) in neuronal target cells of a mammalian host. The viral vector contains a recombinant DNA molecule comprising a B-50/GAP-43 gene operably associated with a promoter, which promoter controls short term, high level expression of the B-50/GAP-43 gene. Preferably, the viral vector is a defective viral vector, in particular a defective herpes virus or an adeno-associated virus. In a specific embodiment, defective herpesvirus, adenovirus, and adeno-associated virus viral vectors containing the rat B-50/GAP-43 gene under control of the human cytomegalovirus immediate early promoter have been prepared. The invention further provides a method for treating nerve damage in a subject. The method comprises introducing a vector comprising a B-50/GAP-43 gene operably associated with a promoter into a damaged nerve tissue of a subject.Type: GrantFiled: August 2, 1996Date of Patent: August 22, 2000Assignees: The Rockefeller University, Rudolf Magnus InstituteInventors: Michael G. Kaplitt, Joost Verhaagen
-
Patent number: 6107288Abstract: Synergistic combinations of nucleoside derivatives, pharmaceutical formulations containing said combinations and use of the combinations in the treatment of retroviral infections are disclosed.Type: GrantFiled: April 27, 1993Date of Patent: August 22, 2000Inventors: Phillip Allen Furman, Jr., George Robert Painter, III
-
Patent number: 6090544Abstract: Disclosed herein are methods and compositions for identifying morphogen analogs. The preferred methods and compositions relate to the discovery that morphogen upregulation of the mouse type X collagen promoter activity is mediated by a MEF-2 like sequence and requires an adjacent AP-1 sequence. Certain methods rest on the use of test cells comprising DNA defining a morphogen-responsive transcription activating element operatively associated with a reporter gene. Other methods rest on the use of DNAs for measuring morphogen-inducible DNA-binding. In certain preferred embodiments, the methods and DNAs involve an osteogenic protein 1 (OP-1) responsive transcription activating element. Substances that mediate interaction with and/or activate the OP-1 responsive transcription activating element are considered herein likely to be useful for reproducing in vivo effects of morphogens such as OP-1.Type: GrantFiled: December 12, 1996Date of Patent: July 18, 2000Assignee: Creative BioMolecules, Inc.Inventors: Shun-ichi Harada, Gideon A. Rodan, Kuber T. Sampath
-
Patent number: 6087128Abstract: A nucleic acid sequence encoding an avian E. coli iss gene and an Iss polypeptide encoded thereby are disclosed. Methods for detecting and using such sequences are also provided as are immunogenic compositions and vaccines.Type: GrantFiled: February 12, 1998Date of Patent: July 11, 2000Assignee: NDSU Research FoundationInventors: Lisa K. Nolan, Shelley M. Horne
-
Patent number: 6083725Abstract: A therepeutic method whereby an individual suspected of having an .alpha.-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human .alpha.-gal A, or (2) purified human .alpha.-gal A obtained from cultured, genetically modified human cells.Type: GrantFiled: September 12, 1997Date of Patent: July 4, 2000Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F. Selden, Marianne Borowski, Frances P. Gillispie, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams
-
Patent number: 6077697Abstract: Methods for preparing cell lines that contain artificial chromosomes, methods for preparation of artificial chromosomes, methods for purification of artificial chromosomes, methods for targeted insertion of heterologous DNA into artificial chromosomes, and methods for delivery of the chromosomes to selected cells and tissues are provided. Also provided are cell lines for use in the methods, and cell lines and chromosomes produced by the methods. In particular, satellite artificial chromosomes that, except for inserted heterologous DNA, are substantially composed of heterochromatin are provided. Methods for use of the artificial chromosomes, including for gene therapy, production of gene products and production of transgenic plants and animals are also provided.Type: GrantFiled: July 15, 1996Date of Patent: June 20, 2000Assignees: Chromos Molecular Systems, Inc., The Biological Research Center of the Hungarian Academy of SciencesInventors: Gyula Hadlaczky, Aladar A. Szalay
-
Patent number: 6071725Abstract: The present invention relates to surface anchoring vectors, a method for preparation of foreign proteins onto a cell surface and use thereof, which uses outer cell membrane protein, ice nucleation protein (NIP) derived from Pseudomonas syringae, a gram-negative bacterium.Type: GrantFiled: December 2, 1997Date of Patent: June 6, 2000Assignee: Korea Institute of Science and TechnologyInventors: Jae Gu Pan, Heung Chae Jung, Seung Hwan Park, Moon Hi Han, Young Hoon Park
-
Patent number: 6063613Abstract: The present invention is directed to the identification of mutant strains of methicillin resistant bacteria, in particular methicillin resistant Staphylococcus aureus, to identify the characteristics of such bacteria and develop drugs that can reverse, inhibit or reduce bacterial resistance to beta lactam antibiotics, e.g., methicillin. The invention particularly relates to identification of a novel mutant strain of methicillin resistant S. aureus that manifests a unique phenotype. The mutant strain lacks unsubstituted pentapeptide and incorporates alanylglutamate- and alanylisoglutamine-containing muropeptides, and accumulates large amounts of the UDP-linked muramyul dipeptide in the cytoplasmic wall precursor pool of the mutant. Based on the phenotypic consequences of the mutation, inhibitors of the lysine addition step in bacterial cell wall biosyntheis are identified as having therapeutic potential for reducing bacterial resistance to beta lactam antibiotics, notably methicillin.Type: GrantFiled: March 15, 1995Date of Patent: May 16, 2000Assignee: The Rockefeller UniversityInventors: Herminia De Lencastre, Alexander Tomasz
-
Patent number: RE45874Abstract: A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area.Type: GrantFiled: July 1, 2014Date of Patent: February 2, 2016Assignee: Sergeant's Pet Care Products, Inc.Inventor: Larry Nouvel
-
Patent number: RE45894Abstract: A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area.Type: GrantFiled: July 1, 2014Date of Patent: February 23, 2016Assignee: Sergeant's Pet Care Products, Inc.Inventor: Larry Nouvel
-
Patent number: RE46152Abstract: Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1° C.-34° C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells.Type: GrantFiled: August 1, 2014Date of Patent: September 20, 2016Assignee: Argos Therapeutics, Inc.Inventors: Rebecca Pogue, Tamara Monesmith, Irina Tcherepanova, Lois Dinterman
-
Patent number: RE46254Abstract: The present invention concerns gp36 immunoreactive compositions for E. canis and gp 47 immunoreactive compositions for E. chaffeensis. In particular, epitopes for E. canis gp36 and E. chaffeensis gp 47 are disclosed. In certain embodiments, the immunoreactive compositions comprise tandem repeats having carbohydrate moieties.Type: GrantFiled: September 15, 2015Date of Patent: December 27, 2016Assignee: Research Development FoundationInventors: Jere W. McBride, Christopher K. Doyle
-
Patent number: RE46284Abstract: The present invention relates to a method for treating a cancer comprising orally administering a composition containing ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m2/day in terms of FTD in 2 to 4 divided portions per to patients in need of the treatment.Type: GrantFiled: December 30, 2015Date of Patent: January 24, 2017Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Tomohiro Emura, Akira Mita
-
Patent number: RE46293Abstract: An embodiment of a method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance is described that comprises the steps of: generating cDNA species from each RNA molecule in an HIV sample population; amplifying at least one first amplicon from the cDNA species, wherein each first amplicon comprises a plurality of amplified copies and is amplified with a pair of nucleic acid primers that define a locus of the first amplicon; clonally amplifying the amplified copies of the first amplicons to produce a plurality of second amplicons wherein a plurality of the second amplicons comprise an immobilized population of substantially identical copies from one of the amplified copies of first amplicons; determining a nucleic acid sequence composition of the substantially identical copies from at least 100 of the immobilized populations in parallel on a single substrate; and detecting one or more sequence variants that occur at a frequency of 5% or less in the nucleic acType: GrantFiled: December 30, 2014Date of Patent: January 31, 2017Assignee: 454 Life Sciences CorporationInventors: Birgitte Binderup Simen, Elizabeth Patricia St. John
-
Patent number: RE46364Abstract: [Object] The main object of the present invention is to provide a fibrosis inhibitor. [Solving Means] The present invention relates to a fibrosis inhibitor containing the heterocyclic derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient; In the formula (1), R1 and R2 are the same or different and each represents an optionally substituted aryl; R3 and R4 are the same or different and each represents hydrogen atom or alkyl; R5 represents hydrogen atom, alkyl or halogen atom; Y represents N or N?O; A represents NR6, and R6 represents hydrogen atom, alkyl, etc.; D represents alkylene or alkenylene which is optionally substituted with hydroxy; E represents phenylene or a single bond; G represents O, S, etc.; and Q represents carboxy, alkoxycarbonyl, etc.Type: GrantFiled: May 16, 2016Date of Patent: April 11, 2017Assignee: NIPPON SHINYAKU CO., LTD.Inventors: Koji Murakami, Takuya Toramoto
-
Patent number: RE46372Abstract: A method of treating hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.Type: GrantFiled: April 4, 2016Date of Patent: April 25, 2017Assignee: THE REGENTS OF THE UNIVERITY OF MICHIGANInventors: Josef M. Miller, Glenn E. Green, Colleen G. LePrell